{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:26:57Z","timestamp":1772119617301,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10637-021-01103-8","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T15:02:26Z","timestamp":1616252546000},"page":"1197-1199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA"],"prefix":"10.1007","volume":"39","author":[{"given":"Shouhua","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhe","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6272-6582","authenticated-orcid":false,"given":"Junlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"key":"1103_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"The Cancer Genome Atlas Research Network","year":"2014","unstructured":"The Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315\u2013322. https:\/\/doi.org\/10.1038\/nature12965","journal-title":"Nature"},{"key":"1103_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/0008-5472.CAN-12-1726","volume":"73","author":"F Janku","year":"2013","unstructured":"Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R (2013) PIK3CA mutation H1047R is associated with response to PI3K\/AKT\/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 73:276\u2013284. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1726","journal-title":"Cancer Res"},{"key":"1103_CR3","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1073\/pnas.0701005104","volume":"104","author":"M Gymnopoulos","year":"2007","unstructured":"Gymnopoulos M, Elsliger M-A, Vogt PK (2007) Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci 104:5569\u20135574. https:\/\/doi.org\/10.1073\/pnas.0701005104","journal-title":"Proc Natl Acad Sci"},{"key":"1103_CR4","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1093\/annonc\/mds057","volume":"23","author":"E Seront","year":"2012","unstructured":"Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP (2012) Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 23:2663\u20132670. https:\/\/doi.org\/10.1093\/annonc\/mds057","journal-title":"Ann Oncol"},{"key":"1103_CR5","doi-asserted-by":"crossref","unstructured":"Yi Z (2019) Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. 9","DOI":"10.1186\/s12885-019-5668-3"},{"key":"1103_CR6","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1158\/1078-0432.CCR-09-3202","volume":"17","author":"E Chiong","year":"2011","unstructured":"Chiong E, Lee I-L, Dadbin A, Sabichi AL, Harris L, Urbauer D, McConkey DJ, Dickstein RJ, Cheng T, Grossman HB (2011) Effects of mTOR inhibitor Everolimus (RAD001) on bladder Cancer cells. Clin Cancer Res 17:2863\u20132873. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-3202","journal-title":"Clin Cancer Res"},{"key":"1103_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12885-017-3196-6","volume":"17","author":"ST Kim","year":"2017","unstructured":"Kim ST, Lee J, Park SH, Park JO, Park YS, Kang WK, Lim HY (2017) Prospective phase II trial of everolimus in PIK3CA amplification\/mutation and\/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer 17:211. https:\/\/doi.org\/10.1186\/s12885-017-3196-6","journal-title":"BMC Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01103-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01103-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01103-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:07:33Z","timestamp":1678493253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01103-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,20]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1103"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01103-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-216259\/v1","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,20]]},"assertion":[{"value":"9 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from the patient for participating and publication of this case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate & publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}